1[1]Sabharwal A,Kerr D.Chemotherapy for colorectal cancer in the metastatic and adjuvant setting:Past,present and future.Expert Rev Anticancer Ther,2007,7 (4):477
2[2]Giacchetti S,Perpoint B,Zidani R,et al.Phase Ⅲ multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.J Clin Oncol,2000,18 (1):136
3[3]Douillard JY,Cunningham D,Roth AD,et al.Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer:A multicentre randomised trial.Lancet,2000,355(9209):1041
4[4]Cunningham D,Humblet Y,Siena S,et al.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan -refractory metastatic colorectal cancer.N Engl J Med,2004,351 (4):337
5[5]Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer.N Engl J Med,2004,350(23):2335
6[6]Guo XD,Harold N,Saif MW,et al.Pharmacokinetic and pharmacodynamic effects of oral eniluracil,fluorouracil and leucovorin given on a weekly schedule.Cancer Chemother Pharmacol,2003,52 (1):79
7[7]Evrard A,Cuq P,Ciccolini J,et al.Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase.Br J Cancer,1999,80(11):1726
8[8]Twelves CJ.Xeloda in adjuvant colon cancer therapy (X -ACT) trial:Overview of efficacy,safety,and cost-effectiveness.Clin Colorectal Cancer,2006,6 (4):278
9[9]Rabik CA,Dolan ME.Molecular mechanisms of resistance and toxicity associated with platinating agents.Cancer Treat Rev,2007,33 (1):9
10[10]Cullen KJ,Newkirk KA,Schumaker LM,et al.Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.Cancer Res,2003,63 (23):8097
